Smoking cessation and COPD

European Respiratory Review

Volumn 22, Issue 127, 2013, Pages 37-43

  Tønnesen, Philip ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bupropion; Chronic obstructive pulmonary disease; Counselling; Nicotine replacement therapy; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE PATCH; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; ADULT; AGED; ALLERGIC REACTION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GROUP THERAPY; HEART INFARCTION; HUMAN; INSOMNIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORBIDITY; NAUSEA; NICOTINE REPLACEMENT THERAPY; ORAL SPRAY; PATIENT COUNSELING; PREVALENCE; REVIEW; SEIZURE; SMOKING CESSATION; SUICIDAL BEHAVIOR; SURVIVAL RATE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; TOBACCO DEPENDENCE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

BENZAZEPINES; BUPROPION; COUNSELING; HUMANS; NICOTINE; NICOTINIC AGONISTS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOXALINES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84874678045     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00007212     Document Type: Review

References (44)

1. Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819-1823.
2. Watson L, Vonk JM, Löfdahl CG, et al. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir Med 2006; 100: 746-753.
3. Vestbo J, Soriano JB, Anderson JA, et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med 2004; 98: 1045-1050.
4. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
5. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
6. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
7. Huang Y, Britton J, Hubbard R, et al. Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database. Tob Control 2012 [Epub ahead of print DOI: 10.1136/tobaccocontrol-2011-050124].
8. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Clinical Practice Guideline. Rockville, U.S. Department of Health and Human Services, 2008.
9. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; 11: CD000146.
10. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4: CD006103.
11. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1: CD000031.
12. National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. National Institute for Clinical Excellence Technology Appraisal Guidance No. 39. 2002. http://www.nice.org.uk/TA039 Date last updated: December 20, 2011. Date last accessed: January 2, 2013.
13. Aveyard P, Begh R, Parsons A, et al. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction 2012; 107: 1066-1073.
14. Stead LF, Lancaster T, Perera R. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2003; 1: CD002850.
15. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2000; 2: CD001007.
16. Sundblad, Larsson K, Nathell L. High rate of smoking abstinence in COPD patients: smoking cessation by hospitalization. Nic Tob Res 2008; 10: 883-890.
17. Murray RP, Nides MA, Istvan JA, et al. Levels of cotinine associated with long-term ad-libitum nicotine polacrilex use in a clinical trial. Addict Behav 1998; 23: 529-535.
18. Lawson GM, Hurt RD, Dale LC, et al. Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. J Clin Pharmacol 1998; 38: 502-509.
19. Tønnesen P, Lauri H, Perfekt R, et al. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J 2012; 40: 548-554.
20. Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334-342.
21. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591-599.
22. Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet 2001; 357: 1571-1575.
23. Hajek P, Jackson P, Belcher M. Long-term use of nicotine chewing gum. Occurrence, determinants, and effect on weight gain. JAMA 1988; 260: 1593-1596.
24. Hughes JR, Gust SW, Keenan R, et al. Long term use of nicotine vs. placebo gum. Arch Intern Med 1991; 151: 1993-1998.
25. Tønnesen P, Mikkelsen K. Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial. Nicotine Tob Res 2013; 15: 419-427.
26. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006; 60: 571-576.
27. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs. sustainedrelease bupropion and placebo for smoking cessation. JAMA 2006; 296: 47-55.
28. Jorenby DE, Hays T, Rigotti NA, et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation. JAMA 2006; 296: 56-63.
29. Brophy JM. ACP Journal Club. Review: varenicline increases risk for serious adverse cardiovascular events in tobacco users. Ann Intern Med 2011; 155: JC4-JC5.
30. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344: e2856.
31. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805.
32. Food US, Drug Administration. FDA Drug Safety Communication: safety review update of Chantix (varenicline) and risk of cardiovascular adverse events. www.fda.gov/Drugs/DrugSafety/ucm330367.htm Date last updated: December 13, 2012. Date last accessed: January 2, 2013.
33. David SP, Strong DR, Munafo MR, et al. Bupropion efficacy for smoking cessation is influenced by DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 2007; 9: 1251-1257.
34. Beyens MN, Guy C, Mounier G, et al. Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Saf 2008; 31: 1017-1026.
35. Strassmann R, Bausch B, Spaar A, et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J 2009; 34: 634-640.
36. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
37. Hilberink SR, Jacobs JE, Bottema BJ, et al. Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Prev Med 2005; 41: 822-827.
38. Wagena EJ, Knipschild PG, Huibers MJH, et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 2286-2292.
39. Pederson LL, Wanklin JM, Lefcoe NM. The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. Int J Addic 1991; 26: 107-119.
40. Crowley TJ, Macdonald MJ, Walter MI. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology 1995; 119: 193-204.
41. Brandt CJ, Ellegaard H, Joensen M, et al. Effect of diagnosis of "smoker's lung". RYLUNG Group. Lancet 1997; 349: 253.
42. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679.
43. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality. Ann Intern Med 2005; 142: 233-239.
44. Tønnesen P, Carrozzi L, Fagerström KO, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29: 390-417.